Backgroud and Objectives: To evaluate conventional Doppler indices and the novel middle cerebral artery (MCA) diastolic deceleration area (DDA) in pregnancies complicated by gestational diabetes mellitus (GDM), and to explore their associations with perinatal outcomes. Prospective case–control study conducted at a tertiary referral perinatology center. Materials and Methods: The study included 83 women with GDM and 92 healthy controls. Standard fetal biometric and Doppler parameters—umbilical artery, MCA, ductus venosus, cerebroplacental ratio, and umbilicocerebral ratio—were assessed, alongside calculation of MCA DDA. Perinatal outcomes were recorded. Results: Most conventional Doppler indices did not differ between groups, except for lower MCA dicrotic notch velocity and higher ductus venosus time-averaged maximum velocity in the GDM group. MCA DDA values did not differ significantly between GDM and control groups (6.67 [5.02–8.20] vs. 7.05 [5.21–8.39] cm·s, p = 0.444) and showed no difference between insulin- and diet-controlled subgroups (p > 0.05). MCA DDA showed significant correlations with gestational age, MCA peak systolic velocity, and birth weight. However, after adjustment for potential confounders, gestational age remained the only independent determinant of MCA DDA. The multivariable analysis evaluating composite adverse neonatal outcomes was limited by the small number of adverse events (n = 14). Conclusions: MCA DDA did not differ between GDM and control pregnancies and primarily reflected gestational age-related physiological variation rather than diabetes specific hemodynamic changes. However, its relationship with adverse neonatal outcomes remains uncertain and requires further investigation in larger prospective studies.
Objective: To evaluate fetal pulmonary artery hemodynamics (PAAT, PAET, PATET) in pregnancies complicated by intrahepatic cholestasis of pregnancy (ICP) and to investigate their association with the aspartate aminotransferase-to-platelet ratio index (APRI). Methods: In this prospective study, 64 ICP cases and 64 healthy pregnancies are included. Doppler measurements of the fetal main pulmonary artery, umbilical artery (UAPI), and middle cerebral artery (MCAPI) were performed by a single operator, and all biochemical analyses were conducted in the same laboratory. APRI was calculated using the standard formula. Results: Doppler evaluation demonstrated significantly higher PAAT, PAET, PATET, UAPI, and MCAPI values in the ICP group (all p < 0.05). AST, ALT, and APRI levels were markedly elevated in ICP pregnancies (all p < 0.001). No significant correlation was observed between PATET and APRI (p = 0.368) or fasting bile acid levels (FBA) (p = 0.116), whereas APRI showed a weak positive correlation with FBA (r = 0.308; p = 0.013). Doppler parameters and APRI values did not differ significantly according to cholestasis severity (10–39/≥40/≥100 μmol/L; all p > 0.05). Conclusions: In ICP, fetal pulmonary artery Doppler indices (PAAT, PAET, PATET) and fetoplacental Doppler parameters are increased; the elevation in PATET is consistent with lower—rather than higher—fetal pulmonary vascular resistance, potentially reflecting accelerated fetal lung maturation or a hemodynamic adaptation to ICP-related physiological perturbations. Despite elevated APRI levels, these biochemical changes do not parallel fetal hemodynamic indicators. These findings suggest that fetal hemodynamic effects in ICP may be independent of biochemical disease severity. PATET is best conceptualized as a hemodynamic monitoring variable complementing bile acid assessment in fetal surveillance, not as a standalone screening or prognostic tool.
Background/Objectives: To identify the clinical factors associated with a multidisciplinary fetal council’s recommendation for termination of pregnancy in fetuses with renal anomalies, to describe how often families followed this recommendation, and to describe outcomes among continued pregnancies. Methods: This retrospective cohort study included 103 singleton pregnancies with a prenatally diagnosed renal or urinary tract anomaly discussed at a tertiary fetal council between December 2023 and July 2026. Renal severity, gestational age at diagnosis, amniotic fluid status, associated fetal abnormalities, and genetic evaluation were examined in relation to the council recommendation. Independent associations were assessed using multivariable logistic regression, Poisson regression with robust variance estimation, and Firth penalized logistic regression. Postnatal outcomes were summarized for pregnancies that continued. Results: A termination recommendation was issued in 59 of 103 pregnancies (57.3%). Of these, 43 families (72.9%) accepted it and the pregnancy was terminated, whereas 16 (27.1%) continued the pregnancy. Later diagnosis and moderate or low renal severity were independently associated with a lower likelihood of a termination recommendation. The presence of an additional fetal anomaly (adjusted odds ratio [aOR] 8.24, 95% confidence interval [CI] 1.59–42.65) and completion of genetic testing (aOR 4.53, 95% CI 1.45–14.15) were independently associated with a higher likelihood of such a recommendation. Among 60 continued pregnancies, 11 intrauterine or neonatal/postnatal deaths occurred (18.3%); mortality was 42.9% in the high-severity group and 5.3% in the low-severity group. The prenatal renal finding was confirmed postnatally in 22 cases, while renal-specific follow-up was unavailable in 18. Conclusions: Termination recommendations issued after prenatal detection of a renal anomaly were shaped by the timing of diagnosis, expected renal prognosis, the wider fetal phenotype, and the availability of genetic information. The observed difference between the council recommendation and the parental decision, together with substantial variation in postnatal outcomes, supports individualized counseling within a multidisciplinary framework.
Background/Objectives: Termination of pregnancy (TOP) following a prenatal diagnosis of congenital heart disease (CHD) is a complex decision shaped by clinical, ethical, and psychosocial factors. This study evaluated the clinical factors associated with parental acceptance of TOP after prenatal diagnosis of CHD in a multidisciplinary counselling setting. Methods: This retrospective cohort study was conducted at a tertiary referral center where fetal CHD cases are evaluated in a multidisciplinary perinatology council. Pregnancies with a prenatal CHD diagnosis for which TOP was medically recommended between December 2023 and February 2026 were included. Maternal, fetal, and genetic data were analyzed. Cardiac severity was classified using the fetal cardiovascular disease severity scale. Because the cohort included only 62 pregnancies, a simplified multivariable logistic regression model with three clinically prespecified variables (four parameters: gestational age, cardiac severity, and genetic-evaluation status) was used to identify variables associated with termination acceptance. Results: Sixty-two pregnancies were included; 41 (66.1%) accepted termination and 21 (33.9%) continued the pregnancy. Maternal characteristics and gestational age at diagnosis were similar between groups. In the multivariable model, genetic-evaluation status was the only variable independently associated with termination acceptance. Compared with cases without genetic testing, both major chromosomal/pathogenic anomalies (aOR 4.97; 95% CI 1.29–19.11; p = 0.020) and a normal genetic-evaluation status (aOR 4.71; 95% CI 1.07–20.77; p = 0.041) were associated with higher termination acceptance. Cardiac severity and gestational age were not independently associated with parental decision. Conclusions: Genetic-evaluation status was associated with parental acceptance of termination after prenatal CHD diagnosis in a multidisciplinary counselling setting; given the small sample size and the selected, council-recommended cohort studied, this association should be interpreted as hypothesis-generating rather than as evidence of a causal or independent predictive effect.
Objective: To assess whether the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), AST-to-platelet ratio index (APRI) and fibrosis-4 (FIB-4) score, derived from first-trimester tests, discriminate intrahepatic cholestasis of pregnancy (ICP) and predict adverse perinatal outcomes within ICP. Materials and Methods: This retrospective case–control study included 115 women with ICP and 64 healthy controls. Indices were derived from 11–14-week values. The composite adverse outcome comprised preterm birth, meconium-stained amniotic fluid, fetal distress, neonatal intensive care admission or a 1-minute Apgar score <7. ROC analysis with DeLong comparisons and logistic regression adjusted for age and body mass index were used. Results: APRI (p < 0.001), NLR (p = 0.002) and SII (p = 0.011) were higher in ICP; FIB-4 was similar. Among derived markers, APRI had the highest area under the curve (AUC 0.786; 95% CI 0.718–0.851); however, ALT alone performed better (AUC 0.895; DeLong p = 0.003), and APRI and SII added nothing to ALT (AUC 0.904; p = 0.465). In the adjusted model, APRI (OR 3.36 per 0.1 unit; 2.16–5.25) and SII (OR 1.45 per 100 units; 1.08–1.96) remained independent. Within the ICP group, no index predicted adverse outcomes; only serum bile acids did (AUC 0.754; OR 2.39 per 10 µmol/L; 1.54–3.69), which persisted, though attenuated, after excluding the protocol-driven preterm component (AUC 0.681). Conclusion: First-trimester APRI and SII carry an early hepatocellular–inflammatory signal in women who later develop ICP, but add no diagnostic value beyond transaminases and do not predict perinatal risk; surveillance and delivery timing should continue to rely on bile acids.